How to Use AI for a Nephrology Practice in 2026: CKD, Dialysis, Transplant, ESRD QIP, KCC & Owner Scorecard
Published 2026-06-01 · 15 min read
TL;DR — nephrology AI stack for 2026.Point AI at six bottlenecks: (1) new-patient + CKD intake with KDIGO heat-map + Tangri kidney-failure risk equation, (2) ambient-scribed CKD + dialysis + transplant SOAP with CPT 90951-90970 + 90935-90947 + 99202-99215 + transplant 99483 / G-codes, (3) AI dashboard for ESRD QIP measures (Kt/V, vascular access, hypercalcemia, STrR, SRR, SHR, ICH CAHPS) + KCC / ACO REACH attribution, (4) anemia (ESA + iron + HIF-PHI roxadustat / daprodustat / vadadustat) + mineral-bone (calcimimetic + phosphate-binder + active vit D) protocol adherence, (5) transplant-referral pipeline + preemptive transplant + living-donor first + paired exchange (UNOS / NKR / APD), (6) HIPAA-safe missed-treatment recovery + recall + review reply. Wrap in a compliance floor: HIPAA + 42 CFR 494 ESRD Conditions for Coverage + AKS/Stark + Sunshine Act + KDIGO + KDOQI + AAKP + ASN + state medical board AI guidance + state AI-scribe consent + FTC Endorsement Guides. Target owner KPI: Kt/V > 1.4 in > 90% of HD pts, AVF/AVG > 80% prevalent, CVC < 10% > 90 days, transplant referral rate > 30% of ESRD < 75 yo, home-dialysis % > 25% prevalent, missed-treatment rate < 8%, and a monthly 90-minute owner scorecard review.
The 7-layer nephrology AI stack (2026)
| Layer | Examples | Owner |
|---|---|---|
| EHR + nephrology module | Epic Renal + Acumen Epic, Oracle Cerner Millennium, athenaOne, NextGen, eCW, Meditech Expanse, FMC eCube + Kinexus, DaVita Snappy + Falcon, US Renal Care USRC Portal | Practice administrator |
| Ambient scribe + AI documentation | DeepScribe, Abridge, Suki Assistant, Nuance DAX Copilot, Heidi, Freed, Sunoh.ai, Nabla, Augmedix | Lead nephrologist |
| Dialysis machine + telemetry AI | Fresenius 2008T BlueStar + Kinexus, Baxter AK 98 + Sharesource, NxStage System One + Nx2me, Outset Tablo, Quanta SC+, B. Braun Dialog iQ, Dialyze Direct, Mozarc Vital, Diality Moda, CVS Kidney Care, Healthmap (Cricket Health) | Medical Director |
| Risk stratification + transplant pipeline | Cricket Health + Healthmap, Renalytix KidneyIntelX FDA-cleared 2023, Strive Health CareMultiplier, InterWell Health, Somatus, Monogram Health, Evergreen Nephrology, Renal Clinical Insights, Tangri 4-var + 8-var KFRE | Practice owner / KCE / ACO |
| Quality + ESRD QIP + KCC dashboard | Acumen Epic Quality, FMC Pulse, DaVita Village Insights, USRC Quality Portal, ArborMetrix, Health Catalyst, Strive Health Atlas, REACH platform via Aledade / Privia / Agilon, KCE platforms | Quality Director |
| Prior-auth + revenue + denial appeal | CoverMyMeds, Glidian, Myndshft, Availity, Waystar, Olive AI, Office Ally, Experian Health, Inovalon, Change Healthcare | Billing manager |
| Patient engagement + HIPAA-safe recall | Weave, NexHealth, Doctible, Solutionreach, Klara, BirdEye, Podium, Phreesia, RevenueWell, Healow, MyChart messaging | Front-office manager |
10 copy-paste prompts for nephrology teams
1) New-patient CKD intake + KDIGO + Tangri risk
You are the nephrology MA. For new patient [NAME], synthesize from the chart + uploaded labs / imaging:
1) CKD stage by KDIGO heat-map: GFR category G1-G5 + albuminuria A1-A3
2) Etiology: diabetic nephropathy, hypertensive nephrosclerosis, GN (IgA, FSGS, membranous, lupus, ANCA), PKD, obstruction, drug-induced, CIN, AIN, CKD of unknown cause
3) Tangri 4-variable KFRE: age, sex, eGFR, ACR — 2 + 5-year risk of kidney failure
4) Tangri 8-variable KFRE: + serum calcium, phosphate, bicarbonate, albumin
5) Red-flags: rapid eGFR decline > 5 mL/min/1.73m²/yr, nephrotic-range proteinuria > 3.5 g/day, hematuria + proteinuria + reduced GFR (RPGN), refractory hyperkalemia, refractory acidosis, uremic symptoms
6) CV risk: ASCVD score + CKD multiplier + Kidney Heart Score
7) Transplant candidacy preliminary screen: age, BMI, comorbidity, social support
8) Anemia + MBD baseline: Hgb, ferritin, TSAT, iPTH, calcium, phosphate, 25-OH vitD, ALP
9) Med list red-flags: NSAIDs, RAAS dose / AKI risk, gadolinium contrast risk if eGFR < 30, metformin / SGLT2 / GLP-1 / DPP-4 dosing
10) Visit-prep packet for the nephrologist
The nephrologist reviews + signs every plan. Document AI-assisted with clinician verification per state AI-scribe rules.
2) Ambient-scribed CKD / dialysis / transplant SOAP
You are the ambient scribe. For visit [PATIENT] [DATE] [VISIT_TYPE]:
1) Auto-draft SOAP with HPI, ROS, exam (volume status, access exam for fistula thrill / bruit / aneurysm, BP standing/sitting), assessment, plan
2) Code suggestions: CPT 99202-99215 office E/M, 90951-90970 ESRD MCP monthly, 90935-90940 in-center HD non-monthly, 90945-90947 PD non-monthly, 90989 ESRD-related training, 99483 cognitive assessment, transplant G-codes G0341-G0344
3) Dialysis-specific: prescription (modality HD/PD/HHD/Nocturnal, frequency, duration, blood flow, dialysate flow, dialyzer, anticoagulation, UF goal, target weight), Kt/V or KRU calc, missed-treatment recovery plan
4) Transplant-specific: candidacy update, immunosuppression (tacrolimus level, MMF, prednisone, basiliximab vs ATG induction), BK / CMV / EBV monitoring, biopsy if indicated
5) Anemia + MBD update with current labs vs target
6) Med reconciliation with renal dose adjustment (Cockcroft-Gault for drug dosing, Lexicomp Renal, GlobalRPh)
7) Follow-up + lab order set
The signing nephrologist verifies + signs. Document AI-assistance per state AI-scribe rules.
3) ESRD QIP + KCC / ACO REACH dashboard
You are the quality director. For [FACILITY/PRACTICE] for [MONTH]:
1) ESRD QIP PY 2026 measures: Kt/V dialysis adequacy (HD spKt/V > 1.2, PD weekly Kt/V > 1.7), Vascular Access Type (AVF/AVG > 80% prevalent, CVC < 10% > 90d), Hypercalcemia, ICH CAHPS, STrR Standardized Transfusion Ratio, SRR Standardized Readmission Ratio, SHR Standardized Hospitalization Ratio, NHSN BSI, Ultrafiltration Rate, Clinical Depression Screening, Medication Reconciliation
2) For each measure: current rate, target, gap, named patients to address
3) KCC / KCE attribution: count of attributed beneficiaries, MA / FFS mix, transplant referrals, transplant waitlist additions, home-dialysis % (PD + HHD), missed treatments, hospitalizations, ER visits
4) ACO REACH (if participating): per-beneficiary spend trend, Total Cost of Care benchmark, quality measure status
5) Compare to MIPS MVP Optimal Care for Kidney Health (PY 2025 first reporting) measures
6) Action items by named clinician + due date
7) Submit electronic CROWNWeb / EQRS data on time
Output a 1-page dashboard + named action list.
4) Anemia + MBD protocol adherence
You are the anemia / MBD coordinator. For each prevalent patient:
1) Anemia: Hgb target 10-11.5 g/dL (KDIGO 2012 + 2024 update), ferritin > 200, TSAT > 20%. ESA (epoetin alfa, darbepoetin, methoxy-PEG-epoetin) dose-titrate per protocol. HIF-PHI alternatives oral roxadustat / daprodustat / vadadustat (where indicated, monitor TE / cancer / liver per FDA label). IV iron (sodium ferric gluconate, iron sucrose, ferumoxytol, ferric derisomaltose) per TSAT + ferritin. Avoid Hgb > 11.5 (TREAT trial).
2) MBD: phosphate target < 5.5, calcium 8.4-10.2, iPTH 2-9× ULN, 25-OH vitD > 30. Phosphate binder (sevelamer, lanthanum, calcium-based, ferric citrate, sucroferric oxyhydroxide, tenapanor); calcimimetic (cinacalcet, etelcalcetide); active vitD (calcitriol, paricalcitol, doxercalciferol).
3) Hyperkalemia chronic mgmt: SZC sodium zirconium cyclosilicate, patiromer; allow RAAS continuation (FIDELIO-DKD, CREDENCE).
4) Acidosis: bicarbonate target > 22 (sodium bicarbonate, veverimer pending).
5) Diabetic CKD: SGLT2 (empagliflozin, dapagliflozin, canagliflozin) eGFR thresholds + holds; finerenone (FIGARO-DKD); GLP-1 agonist (FLOW trial semaglutide).
6) Trigger order set, lab follow-up, and clinician-review queue. Closed-loop confirmation each cycle.
The nephrologist signs orders; AI does not.
5) Transplant referral + preemptive transplant pipeline
You are the transplant coordinator. For [PATIENT_LIST]:
1) Identify candidates: eGFR < 20 (preemptive listing), age, BMI < 40 (most centers), comorbidity, ability to tolerate immunosuppression, social support, financial clearance
2) Tangri KFRE 2-yr risk > 40% prioritized
3) Living-donor first pathway: family / friend / paired exchange (NKR National Kidney Registry, APD Alliance for Paired Donation, UNOS Voucher), social-media donor outreach with HIPAA-compliant template
4) Deceased-donor listing: send to UNOS-listed center within 100 mi, multi-listing if appropriate
5) Documentation: H&P, cardiac clearance (stress + echo per ISHLT), cancer screening (colon / mammo / pap / PSA / skin), dental clearance, vaccinations updated (Hep B, pneumococcal, COVID, RSV, shingles, flu, Hep A), TB screen, HIV/HCV/HBV serologies, HLA typing
6) ESA + iron + transfusion-avoidance pre-transplant (avoid sensitization)
7) Track referrals → evaluations → listings → transplants — KCC / KCE shared-savings driver
8) Post-transplant care coordination: Tac levels, BK PCR, CMV PCR, biopsy as indicated, medication-adherence monitoring (Vivaldi, Mediksa, Medisafe)
Track: ESRD pts < 75 yo with referral % (target > 30%), preemptive transplant rate (target growing), living-donor rate.
6) Vascular access + dialysis catheter management
You are the access coordinator. For each prevalent HD patient:
1) Current access: AVF / AVG / tunneled CVC (TDC) / non-tunneled
2) AVF maturation tracking (KDOQI 2019 + Fistula First): venous mapping, surgeon referral, post-op cannulation timeline (rule of 6s — 6 weeks, 6 mm diameter, 6 mm depth, > 600 mL/min flow)
3) Access surveillance: monthly access-flow, recirculation, dynamic / static venous pressure, KDOQI thresholds for fistulogram + intervention
4) Catheter avoidance: target CVC > 90 days < 10% prevalent (ESRD QIP). Plan to convert each TDC patient.
5) Endovascular AVF (WavelinQ, Ellipsys) for selected patients
6) Infection prevention: NHSN BSI, CHG dressing, antimicrobial lock, exit-site care
7) Access intervention: angioplasty / stent / thrombectomy / declot scheduling at access center
8) Patient + family education with vascular access center referral
Output the named-patient access list with action + due date.
7) Home dialysis (PD + HHD) growth pipeline
You are the home-dialysis champion. For [PRACTICE/FACILITY]:
1) Modality education to all CKD 4 + 5 patients (Treatment Options Education TOPS / DOPPS, Medicare KDE benefit 90989 + 90993)
2) PD candidacy: abdominal exam, hernia screen, social support, home assessment
3) PD start: catheter placement (laparoscopic / open / image-guided), break-in period, training (CAPD / APD / cycler), training facility certification
4) HHD: NxStage System One, Outset Tablo home, Quanta SC+ home — partner requirement, training, water treatment, electrical, safety
5) Track home-dialysis prevalent % (KCC mandate 80% home or transplant by year 4 of CKCC for full shared-savings)
6) Failure-to-thrive transitions: PD-to-HD or HHD-to-in-center conversion plan with re-modality counseling
7) Reimbursement: ESRD PPS bundle (75/year cap on training payments, transitional add-on for home), Medicare home-dialysis support
8) Caregiver education + respite + community resources
Output the named-patient home-dialysis pipeline + conversion list.
8) HIPAA-safe missed-treatment recovery + recall
You are the patient navigator. For each missed dialysis treatment / no-show clinic visit:
1) Same-day outreach SMS + call: HIPAA-safe template (no PHI without auth — minimum-necessary 45 CFR 164.514(d), §164.502(a)(5)(iii) Reproductive Health Privacy Final Rule Dec 2024)
2) Reschedule within 48 hr (CMS missed-treatment recovery quality measure)
3) Triage red-flags: hyperkalemia / fluid overload / chest pain / dyspnea — direct to ED; otherwise reschedule
4) Transportation barrier: NEMT (state Medicaid), ride-share medical (Uber Health, Lyft Healthcare, Roundtrip, Kaizen Health), DaVita / FMC / USRC transportation
5) Adherence root-cause: depression (PHQ-9), pain, family, financial, food insecurity (Feeding America), housing
6) Document refusal-of-treatment with informed consent if patient declines
7) Track missed-treatment rate by patient + clinic (target < 8%)
8) Escalate ICH CAHPS-impact concerns to medical director
Comply with TCPA + state mini-TCPA quiet hours 8am-9pm + 2-party consent recording. Never include lab values / dx / med names in SMS without express patient consent.
9) Prior-auth + denial appeal (transplant work-up, biologics, advanced imaging)
You are the prior-auth lead. For [PATIENT] [SERVICE]:
1) Pull payer policy: Medicare NCD/LCD, Medicare Advantage, commercial (UHC, Aetna, Anthem, Cigna, Humana), Medicaid managed care
2) Documentation: clinical necessity, failed-conservative-care duration, KDIGO / KDOQI / AST / ASN guideline citation, Milliman MCG / InterQual criteria mapped
3) Specific high-denial categories: HIF-PHI roxadustat, finerenone, SGLT2 in CKD 4 (eGFR < 30 boundary), GLP-1 obesity dual-indication, Spravato for treatment-resistant depression in CKD, advanced imaging (MRI w/ gad eGFR < 30 caution NSF, CT w/ contrast eGFR < 30 caution CIN), transplant work-up cardiac MRI / coronary CT, IV iron, voriconazole + therapeutic-drug monitoring
4) Letter of Medical Necessity template + signed by nephrologist
5) Peer-to-peer review schedule with payer medical director
6) Appeal track: 1st level (reconsideration), 2nd level (independent review), state external review, ALJ / Medicare appeals
7) Track denials by payer + reason + outcome — close the loop
Compliance: AKS / Stark / Sunshine on any rep-supplied data. No fee-for-LOMN model.
10) Owner monthly scorecard (the number)
Produce a 1-page nephrology-owner monthly scorecard:
- Quality: Kt/V > 1.4 in HD pts (target > 90%), AVF/AVG prevalent (target > 80%), CVC > 90d (target < 10%), missed-treatment rate (target < 8%), STrR + SRR + SHR vs national, ICH CAHPS top-box, ESRD QIP projected payment reduction
- Growth: new CKD referrals, transplant referrals + listings + transplants, home-dialysis prevalent % (target > 25%, KCC trajectory), preemptive transplants
- KCC / ACO REACH: attributed beneficiaries, total cost of care vs benchmark, projected shared savings
- Operations: clinician panel size + visits / mo, ESRD MCP coding mix (90951-90970), no-show / cancellation %
- Access center / vascular: case volume, complications, on-time
- Financial: collection rate, denial rate by payer, AR aging, payer mix
- Compliance: state medical-board status, DEA + CSOS, Medicare ESRD facility certification, peer-review status, AKS / Stark / Sunshine open-payments review, BAA inventory current
- People: clinician retention, RN / PCT / dialysis-tech retention, fellow recruiting, on-call burden
- Tech: AI tool ROI (hours saved), patient portal adoption %
Flag the 3 highest-priority issues for next month. No more.
Compliance floor (2026) — do not ship without these
- HIPAA 45 CFR 160 + 164 — BAA on every AI vendor that touches PHI, minimum-necessary §164.514, §164.502(a)(5)(iii) Reproductive Health Privacy Final Rule Dec 2024 attestation.
- 42 CFR 494 ESRD Conditions for Coverage — facility certification, medical director, IDT plan-of-care, annual + interim assessment, infection control, water treatment AAMI, governance.
- FDA 510(k) AI-SaMD — Renalytix KidneyIntelX, dialysis-machine AI features (Fresenius BlueStar, Baxter AK 98, Outset Tablo), ambient-scribe (DeepScribe, Abridge, Suki, DAX) all framework-bound.
- State medical-board AI guidance — verification of clinician before signature, patient consent, AI not replacing physician judgment, recordkeeping. CA AB 3030 (Jan 2025), TX SB 815 (Sep 2025), UT HB 452, IL HB 1806 (Jan 2026), NY S1331A pending.
- KDIGO + KDOQI + ASN + AAKP guidelines — CKD evaluation + management, anemia, MBD, hypertension, lipid, dialysis adequacy, vascular access, transplant, AKI, GN.
- CMS ESRD QIP PY 2026 — up to 2% Medicare ESRD payment reduction tied to facility quality measures. CROWNWeb / EQRS data submission deadline.
- CMS KCC + KCF + CKCC + ACO REACH — Kidney Care Choices model with risk-track shared savings. KCE attribution, total cost of care benchmark, home-dialysis + transplant trajectory mandates.
- MIPS MVP Optimal Care for Kidney Health — first reporting PY 2025; cost + quality + improvement-activities + Promoting Interoperability.
- AKS 42 U.S.C. §1320a-7b + Stark §1395nn + dialysis safe harbor 42 CFR 1001.952(s) — Medical Director Agreement at FMV, written, ≥ 1-yr term, set in advance, commercially reasonable.
- Sunshine Act 42 U.S.C. §1320a-7h + Open Payments — every consulting / speaker / royalty / AI-tool subsidy from DaVita, Fresenius, US Renal Care, Outset, NxStage, etc. reported.
- FTC Endorsement Guides 2023 + 2024-2025 + Fake Reviews Rule 16 CFR 465 ($51,744/violation FY 2026) — no incentivized reviews, material-connection disclosure on testimonials.
- TCPA 47 U.S.C. §227 + state mini-TCPA + FCC 2024 one-to-one consent rule — quiet hours 8am-9pm + 2-party consent recording (CA/FL/MA/WA/PA/IL/MT/NH/CT/MD).
- State data-breach + state shield laws — CA AB 352, NY S1066B, WA My Health My Data, MA Ch. 127, IL HB 4664 + 50-state breach-notification patchwork.
60-day AI rollout for a 2-10 nephrologist practice
- Days 1-7: Inventory EHR + dialysis-machine telemetry + KCE / ACO data feeds. Sign BAA with ambient-scribe vendor (DeepScribe / Abridge / Suki / DAX). Train every nephrologist + APP on AI-scribe consent template per state rule.
- Days 8-15: CKD intake + Tangri KFRE workflow (Prompt 1) live in EHR. Risk-stratification queue daily.
- Days 16-25: Ambient-scribe (Prompt 2) on every CKD + dialysis + transplant visit. Sign-off audit weekly.
- Days 26-32: ESRD QIP / KCC dashboard (Prompt 3) live. Named-patient action list to each medical director + access coordinator.
- Days 33-40: Anemia + MBD protocol (Prompt 4) automated. Closed-loop ordering with nephrologist sign-off.
- Days 41-47: Transplant pipeline (Prompt 5) + access pipeline (Prompt 6) + home-dialysis pipeline (Prompt 7) live. Weekly multidisciplinary huddle.
- Days 48-54: Missed-treatment recovery (Prompt 8) + prior-auth (Prompt 9) automation. Denial-appeal templates by payer.
- Days 55-60: Owner monthly scorecard (Prompt 10) live. AKS / Stark / Sunshine open-payments review. First quarterly review meeting.
8 mistakes that sink nephrology AI projects
- Pasting PHI into a public ChatGPT / Claude / Gemini / Copilot consumer tier — HIPAA breach + FTC + state-AG + state-medical-board referral.
- Letting AI sign a dialysis prescription, transplant listing, or controlled substance — state medical-board + DEA + CMS Conditions for Coverage violation.
- Citing AI-generated guidelines or trial data without verifying — Mata v Avianca + Park v Kim 2d Cir 2024 + Morgan & Morgan 2025 sanctions + medical-board referral.
- Skipping AKS / Stark / Sunshine review on dialysis joint ventures + Medical Director Agreements + AI-tool subsidies — federal enforcement risk.
- Missing ESRD QIP measure submission deadline (CROWNWeb / EQRS) — automatic 2% Medicare payment reduction.
- Failing the KCC home-dialysis 80% trajectory by year 4 — loses shared-savings eligibility.
- Advertising "best dialysis" / "guaranteed transplant" / "kidney cure" — state medical-board + FTC Act §5 + AICPA-equivalent advertising violation.
- No AI-scribe consent (per state rule) + no clinician sign-off documentation — board complaint exposure.
FAQ
Can a nephrologist legally use AI to draft a dialysis-rounding note or CKD progress note?
Yes — but the signing nephrologist is fully responsible under state medical-board rules + CMS Conditions for Coverage 42 CFR 494 (ESRD facilities) + Medicare physician supervision. Use ambient-scribe / dialysis-AI tools that are HIPAA BAA-covered (DeepScribe, Abridge, Suki, Nuance DAX, Heidi, Freed) and that document AI-assistance + clinician verification in the chart. State AI-scribe consent statutes apply: CA AB 3030 (Jan 2025), TX SB 815 (Sep 2025), UT HB 452, IL HB 1806 (Jan 2026). Never let AI auto-sign orders for hemodialysis prescription, transplant listing, or controlled substances.
How does AI fit into ESRD QIP, KCC / ACO REACH, and the CMS Kidney Care Choices model?
ESRD QIP (CMS final rule for PY 2026) ties up to 2% of Medicare ESRD payments to facility-level quality measures (Kt/V dialysis adequacy, vascular access type, hypercalcemia, ICH CAHPS, STrR standardized transfusion ratio, SRR, SHR). KCC includes the CKCC (Comprehensive Kidney Care Contracting) and KCF (Kidney Care First) tracks plus the optional Kidney Contracting Entity inside ACO REACH. AI helps with risk stratification (KDIGO heat-map, Tangri 4-variable + 8-variable kidney-failure risk equation), transplant-referral prioritization, anemia + MBD protocol adherence, missed-treatment recovery, and PD-vs-HD home-dialysis growth (KCC mandates 80% home or transplant by year 4 for full shared savings).
What's the AKS / Stark / Sunshine Act exposure when nephrologists co-own dialysis facilities or use industry-paid AI tools?
Nephrology has the highest density of physician-owned dialysis joint ventures + Medical Director Agreements in medicine. AKS 42 U.S.C. §1320a-7b + Stark §1395nn + the dialysis-specific safe harbor (42 CFR 1001.952(s)) require Medical Director arrangement at FMV, written agreement ≥ 1 year, set in advance, commercially reasonable, and not based on volume / value of referrals. ESRD Anti-Markup + Sunshine Act 42 U.S.C. §1320a-7h require open-payments reporting for any consulting / speaker / royalty / AI-tool subsidies from DaVita, Fresenius, US Renal Care, Satellite, Dialyze Direct, Outset Tablo, NxStage, Quanta, etc. AI vendors that bundle dialysis-machine + EHR + risk-strat (Epic Renal Module, Acumen Epic, NxStage Nx2me + Health Cloud) are NOT a kickback per se but every financial relationship needs FMV + open-payments disclosure.
Does the new HHS OCR Reproductive Health Privacy Rule (2024) affect nephrology practices?
Yes — the Dec 2024 final rule under 45 CFR 164.502(a)(5)(iii) prohibits disclosure of PHI for investigation or prosecution of lawful reproductive health care, and requires an attestation before disclosing any PHI for a non-treatment purpose. Nephrologists managing pregnancy + CKD, lupus nephritis, transplant + immunosuppression in pregnancy, or ESRD pregnancy must train staff on the attestation requirement. State shield laws (CA AB 352 2022, NY S1066B 2023, WA My Health My Data 2024, MA Ch. 127, IL HB 4664 2023) layer additional minimum-necessary defaults.
What ROI can a 2-10 nephrologist practice expect from AI in the first 12 months?
Realized gains: 30-50% faster dialysis-rounding documentation (ambient-scribe + dialysis-AI), 20-30% reduction in ESRD-QIP missed-measure exposure (real-time dashboard + missed-treatment recovery), 1.5-2x increase in transplant referrals (Tangri risk + preemptive transplant pathway), 40%+ reduction in anemia / MBD protocol drift (closed-loop ordering), 25%+ growth in home-dialysis census (PD-first + HHD pipeline) which is critical for KCC shared savings. Owner scorecard (Prompt 10) is where Kt/V adequacy %, vascular access AVF/AVG vs CVC, transplant referral rate, and home-dialysis % actually move.
Sources + further reading
- HIPAA 45 CFR 160 + 164 + Reproductive Health Privacy Final Rule (Dec 2024)
- 42 CFR 494 ESRD Conditions for Coverage
- KDIGO Clinical Practice Guidelines + KDOQI + ASN + AAKP
- CMS ESRD QIP PY 2026 + CMS KCC (CKCC + KCF) + ACO REACH + KCE
- MIPS MVP Optimal Care for Kidney Health
- AKS 42 U.S.C. §1320a-7b + Stark §1395nn + dialysis safe harbor 42 CFR 1001.952(s) + Sunshine Act
- FDA 510(k) AI-SaMD framework + 2024 PCCP
- State medical-board AI guidance (CA AB 3030, TX SB 815, UT HB 452, IL HB 1806)
- FTC Endorsement Guides 2023 + Fake Reviews Rule 16 CFR 465
- Mata v Avianca SDNY 2023 + Park v Kim 2d Cir 2024 + Morgan & Morgan 2025 sanctions
- UNOS, NKR, APD, ASN Transplant, AST